BreakBio Appoints Greg Lizée as Chief Scientific Officer
Nov 20, 2026 | By Kuldeep Jangid

BreakBio has appointed Greg Lizée, Ph.D., as it's new chief scientific officer. He joins the company from The University of Texas MD Anderson Cancer Center, and brings strong experience in tumor immunology, T-cell biology and cancer vaccines.
Dr. Lizée has led four clinical trials involving more than 100 cancer patients and has published over 100 research papers. His research focuses on finding new cancer targets, developing personalized cancer vaccines and studying how the immune system responds to cancer.
Dr. Lizée led a Phase 1b clinical trial of a personalized cancer vaccine for patients with advanced non-small cell lung cancer. Published in 2021, the study found positive responses in seven of the 24 vaccinated patients, including one complete response.
Read More:Everful Raises $48.5 Million in Series A Funding Round
RECOMMENDED FOR YOU
[Funding alert] NYC-based AgentSmyth Secures $2.5Million in Seed Funding
Devin Jacobs
Apr 18, 2024
Over the past 10 years, he has also worked on personalized cancer vaccine trials for multiple myeloma, pancreatic cancer, and colorectal cancer at MD Anderson Cancer Center.
His experience will support BreakBios development of BreakVax, a personalized cancer treatment designed to help T cells identify, and attack cancer cells.
"Greg brings deep expertise in selecting tumor targets and designing vaccines to help the immune system recognize and attack cancer," said Roy de Souza, Chief Executive Officer and Co-Founder of BreakBio. "Through his work at MD Anderson, he has been directly involved in developing personalized cancer vaccines and evaluating them in clinical trials.
About BreakBio
Founded in 2019 by Roy de Souza, BreakBio develops personalized treatments for cancer, and other diseases. Its medicines are designed to target the specific needs of each patient. The company aims to develop effective personalized cancer treatments that can be used across a wide range of cancer types.

Read More:Linq Raises $90M in Funding Led by Andreessen Horowitz








